AGEN Insider Filing: Garo Armen Adds 3,951 Shares for Salary
Rhea-AI Filing Summary
Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc. (AGEN), received 3,951 shares of common stock as salary in lieu of cash, issued under the company's equity plan. The shares were issued at the closing price of $4.14 on 10/03/2025 and are fully vested on issuance. After the transaction, Dr. Armen directly beneficially owns 282,393 shares, with additional indirect holdings of 31,298 and 28,950 through retirement accounts and trusts/partnership interests respectively. The filing notes that the stock payment was approved by the Compensation Committee and represents the net amount for the payroll period ending 10/03/2025.
Positive
- Compensation aligned with shareholders via stock payment of 3,951 shares
- Shares fully vested on issuance, eliminating future vesting uncertainty
- Clear disclosure of direct and indirect holdings totaling reported block positions
Negative
- Modest increase in outstanding shares from paying salary in stock instead of cash
Insights
TL;DR: CEO received salary paid in stock; transaction is routine compensation, not an option exercise.
Issuing 3,951 shares as salary converts cash compensation into equity, aligning pay with shareholder outcomes and immediately increasing the CEO's direct holdings to 282,393 shares. The shares are fully vested on issuance, so there is no future vesting schedule tied to this grant.
This move depends on the company's compensation policy and the Compensation Committee's approval; investors should note the immediate change in share count and the presence of additional indirect holdings in IRA and trust structures, which affect total beneficial ownership reporting over the near term.
TL;DR: Compensation committee-approved stock salary raises governance transparency but slightly increases outstanding shares.
Paying salary in equity rather than cash was authorized and disclosed; the report clarifies the forms of indirect ownership (IRA, GRAT, partnership) and the reporter's role as CEO and chairman. Full vesting at issuance reduces complexity around future forfeiture or clawback timing.
Key items to watch include any recurring use of equity for cash substitution and whether similar practices materially expand share count over Q4 2025, which could modestly affect per-share metrics if continued.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 3,951 | $4.14 | $16K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending October 3, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance. $4.14 is the closing price of our Common Stock on October 3, 2025, the last trading day for the payroll date for the pay period ending October 3, 2025. Shares are held in Dr. Armen's IRA accounts. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
